Clinical Trials Logo

FXS clinical trials

View clinical trials related to FXS.

Filter by:
  • None
  • Page 1

NCT ID: NCT03862950 Recruiting - Clinical trials for Intellectual Disability

A Trial of Metformin in Individuals With Fragile X Syndrome (Met)

Start date: May 24, 2019
Phase: Phase 2
Study type: Interventional

This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 35 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.

NCT ID: NCT03569631 Completed - Fragile X Syndrome Clinical Trials

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

Start date: July 9, 2018
Phase: Phase 2
Study type: Interventional

This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome. Subjects will receive both active treatment with BPN14770 capsules and matching placebo capsules in the course of the study. One treatment will be administered during each of the 12-week study periods.

NCT ID: NCT03479476 Recruiting - Clinical trials for Intellectual Disability

A Trial of Metformin in Individuals With Fragile X Syndrome

Met
Start date: April 30, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 25 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.